Clinical Trials Logo

Tuberculosis (TB) clinical trials

View clinical trials related to Tuberculosis (TB).

Filter by:

NCT ID: NCT06272812 Not yet recruiting - Tuberculosis (TB) Clinical Trials

A Study to Evaluate the Efficacy, Safety and Immunogenicity of MTBVAC in IGRA Positive Adolescents and Adults Living in a TB Endemic Region.

Start date: September 2024
Phase: Phase 2
Study type: Interventional

A Phase 2b, double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety and immunogenicity of a candidate tuberculosis (TB) vaccine, MTBVAC, against TB disease in interferon gamma release assay positive adolescents and adults aged 14-45 years, living in a TB endemic region.

NCT ID: NCT04333485 Recruiting - Tuberculosis (TB) Clinical Trials

Tuberculosis (TB) Aftermath

Start date: January 29, 2021
Phase: N/A
Study type: Interventional

TB Aftermath will compare effectiveness, cost-effectiveness and feasibility of two ACF strategies for detecting recurrent TB and provide evidence needed to implement and scale the preferred ACF strategy. The specific aims are: Primary Aim 1: To conduct a non-inferiority randomized trial to measure the comparative effectiveness of two potentially implementable ACF strategies within India's National TB Elimination Program (NTEP), conducted by existing NTEP healthcare workers (HCWs): (i) home-based ACF (HACF) and (ii) telephonic ACF (TACF). Primary Aim 2: To characterize implementation processes of the ACF strategies using the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) framework to inform future scale-up and sustainability. Primary Aim 3: To model the impact and cost effectiveness of the ACF strategies evaluated in the trial, and of potential alternative strategies for the targeting and timing of those strategies. Secondary Aim: To measure the association of the severity, chronicity and progression of post-TB lung impairment with recurrent TB disease.

NCT ID: NCT04243031 Withdrawn - Tuberculosis (TB) Clinical Trials

QuantiFERON Access Clinical Performance Study Protocol

Start date: April 1, 2020
Phase:
Study type: Observational

Approximately 225 samples, obtained from participants with varying risk factors for TB infection and disease, will be tested using the QFT Access Kit and the comparator device QFT-Plus.

NCT ID: NCT03929705 Completed - Tuberculosis (TB) Clinical Trials

Assessing the Ability of the T-SPOT®.TB Test

IQ
Start date: May 2, 2019
Phase:
Study type: Observational

The primary objective of this clinical research study is to demonstrate performance of the normalized TB specific lymphocyte response in identifying patients with active TB disease. The secondary exploratory objective is to demonstrate that active TB cannot be identified using an antigen-to-mitogen ratio derived from an ELISA-based IGRA.

NCT ID: NCT03808636 Recruiting - Tuberculosis (TB) Clinical Trials

Innovative Reagents for Improving Rapid Diagnosis of Mycobacterial Infections

TIKA_TB
Start date: June 2015
Phase:
Study type: Observational

The purpose of this study is to quantitate the speed of new culture method using 'Tika' media and compare with conventional systems

NCT ID: NCT01879163 Completed - Tuberculosis (TB) Clinical Trials

Phase I Trial Evaluating Safety and Immunogenicity of MVA85A-IMX313 Compared to MVA85A in BCG Vaccinated Adults

Start date: July 2013
Phase: Phase 1
Study type: Interventional

This is a Phase I trial to evaluate the safety and immunogenicity of MVA85A-IMX313 vaccination compared to MVA85A vaccination, in BCG vaccinated adults.

NCT ID: NCT01875952 Active, not recruiting - Clinical trials for Human Immunodeficiency Virus (HIV)

Diagnosis and Treatment of Co-infection With Human Immunodeficiency Virus /Latent Tuberculosis Infection (HIV/TBL)

HIV/TB
Start date: May 2010
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine of once identified to the subjects infected with human immunodeficiency virus (positive VIH), to diagnose latent Tuberculosis, and to treat her with isoniazid for six months, measuring the production of Interferon range pre and posttreatment, to evaluate this way the result of the treatment on the immune response

NCT ID: NCT00730795 Completed - Tuberculosis (TB) Clinical Trials

Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine Given to PPD-Negative Adults

Start date: January 2004
Phase: Phase 1
Study type: Interventional

This Phase I study will evaluate the safety and immunogenicity of two doses GSK Biologicals' candidate TB vaccine (692342) according to a 0, 1, 2 months schedule in PPD-negative adults.

NCT ID: NCT00600782 Completed - Tuberculosis (TB) Clinical Trials

Immunogenicity and Safety of a Candidate Tuberculosis (TB) Vaccine Given to Healthy Adults in a TB-endemic Region

Start date: February 5, 2008
Phase: Phase 2
Study type: Interventional

This study will assess the safety and immunogenicity of a GSK Biologicals' candidate TB vaccine administered at 0, 1 months to healthy adults living in a TB-endemic region. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

NCT ID: NCT00291889 Completed - Tuberculosis (TB) Clinical Trials

Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F/AS02 in Healthy PPD-negative Adults.

Start date: July 2004
Phase: Phase 1
Study type: Interventional

Vaccination against tuberculosis (TB) /healthy PPD-negative adults aged 18 to 45 years.Three doses of primary vaccination followed by a booster dose after completion of primary vaccination course. Booster vaccination will be given only to subjects receiving the candidate tuberculosis vaccines and not to the subjects receiving active comparators or control.